Evidence map›Paper›PMID 40732008›Full record

ReviewMicroorganisms2025

Carbapenem Resistance in

Joyce de Souza, Helena Regina Salomé D'Espindula, Isabel de Farias Ribeiro, Geiziane Aparecida Gonçalves, Marcelo Pillonetto, Helisson Faoro

Abstract readReview
In one paragraph

Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Virulence · 2026
    Review
  2. Article
  3. Article
  4. Rapid delineation ofMicrobiology spectrum · 2026
    Article
  5. Characterization ofAntibiotics (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Review
  8. Redefining Antimicrobial Resistance inInternational journal of molecular sciences · 2026
    Review
  9. Article
  10. Article
  11. New Insights intoPathogens (Basel, Switzerland) · 2026
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Six Years ofAntibiotics (Basel, Switzerland) · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joyce de SouzaLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation FIOCRUZ, Curitiba 81350-010, Brazil.
Helena Regina Salomé D'EspindulaLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation FIOCRUZ, Curitiba 81350-010, Brazil.
Isabel de Farias RibeiroLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation FIOCRUZ, Curitiba 81350-010, Brazil.
Geiziane Aparecida GonçalvesMolecular Bacteriology Section, Laboratório Central de Saúde Pública do Estado LACEN-PR, Curitiba 83060-500, Brazil.
Marcelo PillonettoMolecular Bacteriology Section, Laboratório Central de Saúde Pública do Estado LACEN-PR, Curitiba 83060-500, Brazil.ORCID 0000-0003-2896-3186
Helisson FaoroLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation FIOCRUZ, Curitiba 81350-010, Brazil.

Funding

Fiocruz ICC-008-FIO-21-35
6 · The paper itself

Abstract

The global rise of carbapenem-resistant

Indexed as

Acinetobacter baumanniialternative therapiesantimicrobial peptidesartificial intelligencebeta-lactamasescarbapenem resistanceefflux pumpsphage therapy

Identifiers

PMID40732008
PMCPMC12299412

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.